review · Current Oncology
This research explores the application of CRISPR/Cas9 gene editing technology in cancer treatment. CRISPR/Cas9 has significantly advanced gene function science due to its high specificity and efficiency, enabling accurate and rapid whole-genome screening. This capability simplifies the development of disease-specific gene therapies. The technology can modify genomes to study tumor origins, development, and metastasis, and has seen increasing use in tumor treatment research. CRISPR/Cas9 offers a method to treat cancer by removing specific genes or correcting mutations. Numerous preliminary studies have been conducted in this area, suggesting its potential for treating gene-level tumors. The review highlights how CRISPR/Cas9-based personalised and targeted medicines could shape future tumor treatment strategies. It aims to provide references for future research into malignancy pathogenesis and treatment.
Understanding how CRISPR/Cas9 works in cancer treatment is crucial because it offers a precise way to target the genetic roots of the disease. This technology could lead to more effective and personalised therapies, moving beyond traditional treatments to address cancer at a fundamental genetic level.
This research highlights the potential of CRISPR/Cas9 for developing advanced cancer therapies. It could enable the creation of personalised and targeted medicines for treating gene-level tumors, benefiting patients with various malignancies. The abstract indicates that numerous preliminary studies have been conducted, suggesting this is early-stage research with significant future development required before clinical application.
AI-generated from the published abstract. Always read the original work before citing.
Gene editing, especially with clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9), has advanced gene function science. Gene editing's rapid advancement has increased its medical/clinical value. Due to its great specificity and efficiency, CRISPR/Cas9 can accurately and swiftly screen the whole genome. This simplifies disease-specific gene therapy. To study tumor origins, development, and metastasis, CRISPR/Cas9 can change genomes. In recent years, tumor treatment research has increasingly employed this method. CRISPR/Cas9 can treat cancer by removing genes or correcting mutations. Numerous preliminary tumor treatment studies have been conducted in relevant fields. CRISPR/Cas9 may treat gene-level tumors. CRISPR/Cas9-based personalized and targeted medicines may shape tumor treatment. This review examines CRISPR/Cas9 for tumor therapy research, which will be helpful in providing references for future studies on the pathogenesis of malignancy and its treatment.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/curroncol30020152
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
